Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 17/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5406755 | 0.87 | MAOA (1.00) | MAOACYP3A4CYP2D6MAOB | |
| SCHEMBL5758440 | 0.85 | MAOA (0.63) | MAOACYP3A4CYP2D6CYP2C9MAOB | |
| SCHEMBL5388507 | 0.84 | MAOA (0.79) | MAOACYP3A4CYP2D6CYP2C9MAOB | |
| SCHEMBL5385505 | 0.83 | MAOA (0.75) | MAOACYP3A4CYP2D6CYP2C9MAOB | |
| SCHEMBL3328495 | 0.82 | CYP3A4 (0.79) | MAOACYP3A4CYP2D6CYP2C9MAOB | |
| SCHEMBL3328493 | 0.82 | CYP3A4 (0.79) | MAOACYP3A4CYP2D6CYP2C9MAOB | |
| SCHEMBL3328501 | 0.82 | CYP3A4 (0.79) | MAOACYP3A4CYP2D6CYP2C9MAOB | |
| SCHEMBL5385518 | 0.82 | MAOA (0.72) | MAOACYP3A4CYP2D6CYP2C9MAOB | |
| SCHEMBL14560659 | 0.80 | MAOA (0.70) | MAOACYP3A4CYP2D6MAOB | |
| SCHEMBL11983302 | 0.79 | MAOA (0.73) | MAOACYP3A4CYP2D6CYP2C9MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186738-B2 | Antibacterial oxalidinones | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | claimed |
| US-20060079695-A1 | antibiotics such as (5R)-3-[3-Fluoro-4-(3-methylisoxazol-5-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one, having effective activity against both grampositive and gramnegative pathogens | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | US | claimed |
| US-7186738-B2 | Antibacterial oxalidinones | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| US-7186738-B2 | Antibacterial oxalidinones | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| US-7186738-B2 | Antibacterial oxalidinones | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| US-20060079695-A1 | antibiotics such as (5R)-3-[3-Fluoro-4-(3-methylisoxazol-5-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one, having effective activity against both grampositive and gramnegative pathogens | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | US | disclosed |
| EP-1603903-A1 | ANTIBACTERIAL OXALIDINONES | AstraZeneca AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004083206-A1 | ANTIBACTERIAL OXALIDINONES | ASTRAZENECA AB (SE) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079695-A1 | antibiotics such as (5R)-3-[3-Fluoro-4-(3-methylisoxazol-5-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one, having effective activity against both grampositive and gramnegative pathogens | HRH1, HRH2, HDHD5 | MAOA 527/4885CYP3A4 1221/4885CYP2D6 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.